3411 studies found for:    novartis
Show Display Options
RSS Create an RSS feed from your search for:
novartis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
Conditions: Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal ACWY Polysaccharide Vaccine;   Biological: MenACWY  CRM (19 to 55 years);   Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: Novartis MenACWY Vaccine (56 to 65 Years)
2 Recruiting Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus;   Drug: Sandostatin LAR Depot
3 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Conditions: Meningococcal Infections;   Meningococcal Meningitis
Interventions: Biological: MenACWY CRM;   Biological: Meningococcal ACWY Conjugate vaccine
4 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
Conditions: Meningococcal Meningitis;   Human Papillomavirus Infection;   Pertussis;   Tetanus
Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine;   Biological: Tdap Vaccine
5 Completed Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV NZ;   Biological: Placebo
6 Completed
Has Results
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM;   Biological: Licensed meningococcal ACWY vaccine
7 Completed Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Condition: Healthy
Interventions: Drug: CJ Amlodipine/Valsartan 10/160mg;   Drug: Novartis Exforge 10/160mg
8 Completed Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
Condition: Healthy
Intervention: Drug: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
9 Completed
Has Results
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Condition: Prevention of Meningococcal Disease
Interventions: Biological: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation);   Biological: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation);   Biological: MenACWY PS (MenACWY-CRM, polysaccharide vaccine);   Biological: HBV (Hepatitis B vaccine);   Biological: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197);   Biological: MMR (Measles, Mumps and Rubella vaccine);   Biological: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine);   Biological: Menjugate (Men C conjugated vaccine)
10 Active, not recruiting Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: nilotinib
11 Recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107
12 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
13 Recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
14 Not yet recruiting An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Condition: Solid Tumors
Intervention: Drug: dovitinib
15 Recruiting Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Condition: Neoplasms
Intervention: Drug: Everolimus
16 Recruiting Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: Hematologic Neoplasms
Intervention: Drug: Panobinostat
17 Recruiting Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinant vaccine together with routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age);   Biological: Routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
18 Completed Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal B Recombinant Vaccine in Adolescents Aged 11-17 Years
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinat vaccine;   Biological: Meningococcal ACWY-CRM conjugate vaccine and placebo
19 Completed
Has Results
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: MenC-CRM LIQ;   Biological: MenC-CRM ROS;   Biological: MenC-CRM EMV
20 Completed
Has Results
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib-IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years